Propensity score-matched analysis comparing dose-escalated intensity-modulated radiation therapy versus external beam radiation therapy plus high-dose-rate brachytherapy for localized prostate cancer

Jörg Tamihardja1 · Ingulf Lawrenz1 · Paul Lutyj1 · Stefan Weick1 · Matthias Guckenberger2 · Bülent Polat1 · Michael Flentje1

Received: 27 January 2022 / Accepted: 20 April 2022 / Published online: 12 May 2022 © The Author(s) 2022

Abstract

Purpose Dose-escalated external beam radiation therapy (EBRT) and EBRT+ high-dose-rate brachytherapy (HDR-BT) boost are guideline-recommended treatment options for localized prostate cancer. The purpose of this study was to compare long-term outcome and toxicity of dose-escalated EBRT versus EBRT+ HDR-BT boost.

Methods From 2002 to 2019, 744 consecutive patients received either EBRT or EBRT+ HDR-BT boost, of whom 516 patients were propensity score matched. Median follow-up was 95.3 months. Cone beam CT image-guided EBRT consisted of 33 fractions of intensity-modulated radiation therapy with simultaneous integrated boost up to 76.23 Gy (D\text{Mean}). Combined treatment was delivered as 46 Gy (D\text{Mean}) EBRT, followed by two fractions HDR-BT boost with 9 Gy (D\text{90}). Propensity score matching was applied before analysis of the primary endpoint, estimated 10-year biochemical relapse-free survival (bRFS), and the secondary endpoints metastasis-free survival (MFS) and overall survival (OS). Prognostic parameters were analyzed by Cox proportional hazard modelling. Genitourinary (GU)/gastrointestinal (GI) toxicity evaluation used the Common Toxicity Criteria for Adverse Events (v5.0).

Results The estimated 10-year bRFS was 82.0% vs. 76.4% (p = 0.075) for EBRT alone versus combined treatment, respectively. The estimated 10-year MFS was 82.9% vs. 87.0% (p = 0.195) and the 10-year OS was 65.7% vs. 68.9% (p = 0.303), respectively. Cumulative 5-year late GU\geq grade 2 toxicities were seen in 23.6% vs. 19.2% (p = 0.086) and 5-year late GI\geq grade 2 toxicities in 11.1% vs. 5.0% of the patients (p = 0.002); cumulative 5-year late grade 3 GU toxicity occurred in 4.2% vs. 3.6% (p = 0.401) and GI toxicity in 1.0% vs. 0.3% (p = 0.249), respectively.

Conclusion Both treatment groups showed excellent long-term outcomes with low rates of severe toxicity.

Keywords Long-term outcome · Dose escalation · High-dose-rate brachytherapy boost · Propensity score matching · Toxicity

Data availability statement for this work The data that support the findings of this study are available from the corresponding author upon reasonable request.

Jörg Tamihardja tamihardja_j@ukw.de
Ingulf Lawrenz lawrenz_i@ukw.de
Paul Lutyj lutyj_p@ukw.de
Stefan Weick weick_s@ukw.de
Matthias Guckenberger matthias.guckenberger@usz.ch
Bülent Polat polat_b@ukw.de
Michael Flentje flentje_m@ukw.de

1 Department of Radiation Oncology, University of Wuerzburg, Josef-Schneider-Str. 11, 97080 Würzburg, Germany
2 Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
Introduction

External beam radiation therapy (EBRT) and EBRT combined with high-dose-rate brachytherapy (HDR-BT) boost are well-established options for treating localized prostate cancer. Both radiation therapy modalities are widely practiced, but the question arises of which modality offers the best oncologic outcome while minimizing toxicity. Although HDR-BT offers excellent dose conformity, EBRT may be beneficial for ablating periprostatic disease extension in high-risk cancer [1]. Several randomized controlled trials showed an increase in biochemical control by dose escalation, which Hoskin et al. was able to demonstrate for bion in high-risk cancer [1]. Several randomized controlled trials showed an increase in biochemical control by dose escalation, which Hoskin et al. was able to demonstrate for bion in high-risk cancer [1]. Several randomized controlled trials showed an increase in biochemical control by dose escalation, which Hoskin et al. was able to demonstrate for bion in high-risk cancer [1].

This retrospective single-center analysis is based on 744 consecutive patients treated between 2002 and 2019 with either EBRT (n=406) or EBRT+HDR-BT boost (n=338) for localized prostate cancer. All patients had pathologically confirmed prostate cancer. Stratification was conducted according to the risk group classification of D’Amico et al. [10]. Additive androgen deprivation therapy was prescribed at the discretion of the treating urologist and recommended for patients with intermediate-risk (6 months) and high-risk disease (24–36 months).

Materials and methods

Study design and participants

This retrospective single-center analysis is based on 744 consecutive patients treated between 2002 and 2019 with either EBRT (n=406) or EBRT+HDR-BT boost (n=338) for localized prostate cancer. All patients had pathologically confirmed prostate cancer. Stratification was conducted according to the risk group classification of D’Amico et al. [10]. Additive androgen deprivation therapy was prescribed at the discretion of the treating urologist and recommended for patients with intermediate-risk (6 months) and high-risk disease (24–36 months).

Treatment

The treatment procedures have been described in detail before and will be summarized briefly in the following [11, 12]. For the EBRT cohort, radiation therapy was delivered with intensity-modulated radiation therapy (IMRT) or volumetric modulated arc therapy (VMAT) in 33 fractions with simultaneous integrated boost and two dose levels of 1.82 Gy and 2.31 Gy per fraction, resulting in a prescribed planning target volume (PTV) dose of 60.06 Gy (Dmax) and a PTV Boost mean dose of 76.23 Gy. Concerning contouring, a clinical target volume (CTV), CTV_{P,SV}, was generated which consisted of the prostate and the proximal seminal vesicles, whereas the CTV_{P,SV} included the prostate and the whole seminal vesicles. The PTV Boost was defined by placing a 5-mm margin around CTV_{P,SV} with avoidance of the rectum. The PTV was created with a 10-mm margin around CTV_{P,SV} in all but the dorsal direction, where a 7-mm margin was applied.

For the combined treatment cohort, EBRT was delivered with 3D-conformal radiation therapy, IMRT, or VMAT in 23 fractions with 2 Gy per fraction, resulting in a prescribed PTV dose of 46 Gy (D_{max}). A CTV was generated consisting of the prostate and the seminal vesicles. The PTV was created by a 10-mm margin around the CTV in all but the dorsal direction, where a 7-mm margin was used. Approximately 2 weeks after completion of EBRT, two HDR-BT boost fractions were performed with a 14-day interval between the two applications. The HDR-BT boost PTV was defined as the entire prostate without the seminal vesicles and additional margin. The prescription dose for the PTV was 9 Gy (D_{max}) per fraction. Pinnacle® (Philips Radiation Oncology Systems, Fitchburg, WI, USA) was used for EBRT treatment planning for both treatment cohorts.

Outcomes

Biochemical failure was defined according to the Phoenix definition as nadir plus $a\geq 2$-ng/ml increase in prostate-specific antigen (PSA). Biochemical relapse-free survival, defined as the time between the conclusion of radiation therapy treatment and the date of biochemical failure, was the primary reported endpoint of this retrospective study. Secondary endpoints were metastasis-free survival, overall survival, and the 5-year cumulative incidence of gastrointestinal and genitourinary toxicity. Metastasis-free survival was defined as the time between the end of radiation therapy and the date of occurrence of distant metastasis diagnosed by imaging. The time between the end of treatment and the date of death from any cause was defined as overall survival. Patients alive or lost to follow-up at the time of analysis were censored at the date of last contact. Follow-up was defined as the time between the date of the end
Table 1  Baseline characteristics for patients who underwent external beam radiotherapy versus those who received external beam radiotherapy plus high-dose-rate brachytherapy boost before and after propensity score matching

| Characteristic | Unmatched (complete) dataset | Matched (1:1) dataset | p-value* | Unmatched (complete) dataset | Matched (1:1) dataset | p-value* |
|---------------|------------------------------|-----------------------|----------|------------------------------|-----------------------|----------|
|                | EBRT (N= 406)                | EBRT + HDR-BT (N= 338) |          | EBRT (N= 258)                | EBRT + HDR-BT (N= 258) |          |
| Follow-up (months) | 68.3 (49.3, 104.5)          | 101.8 (65.7, 143.0)   | <0.001   | 75.9 (53.8, 117.2)           | 110.2 (67.5, 150.7)   | <0.001   |
| KPS (%)       | 90 (90, 100)                | 90 (90, 100)          | <0.001   | 90 (80, 100)                 | 90 (90, 100)          | <0.001   |
| Age at RT (years) | 73.7 (68.6, 76.9)          | 69.0 (64.3, 73.3)     | 0.003    | 72.3 (66.8, 76.4)           | 71.0 (66.0, 74.5)     | 0.003    |
| PSA at diagnosis (ng/mL) | 8.3 (5.4, 16.4)        | 10.1 (6.5, 20.4)      | 0.003    | 10.2 (6.3, 21.6)           | 10.5 (6.4, 21.5)      | 0.860    |
| PSA at diagnosis, n (%) | – –                      | 0.010                 |          | – –                         | 0.779                 |          |
| <10ng/mL      | 242 (59.6)                  | 164 (48.5)            |          | 126 (48.8)                  | 121 (46.9)            |          |
| 10–20ng/mL    | 81 (20.0)                   | 88 (26.0)             |          | 63 (24.4%)                  | 70 (27.1)             |          |
| >20ng/mL      | 83 (20.4)                   | 86 (25.4)             |          | 69 (26.7%)                  | 67 (26.0)             |          |
| Gleason score, n (%) | – –                      | <0.001                |          | – –                         | 0.197                 |          |
| ≤6            | 133 (32.8)                  | 63 (18.6)             |          | 61 (23.6)                   | 55 (21.3)             |          |
| 7             | 170 (41.9)                  | 173 (51.2)            |          | 120 (46.5)                  | 140 (54.3)            |          |
| ≥8            | 99 (24.4)                   | 100 (29.6)            |          | 77 (29.8)                   | 63 (24.4)             |          |
| Missing, n (%) | 4 (1.0)                    | 2 (0.6)               |          | – –                         | – –                   |          |
| Stage, n (%)  | – –                        | <0.001                |          | – –                         | 0.144                 |          |
| ≤T2a          | 316 (77.8)                  | 206 (60.9)            |          | 175 (67.8)                  | 165 (64.0)            |          |
| T2b           | 7 (1.7)                    | 13 (3.8)              |          | 5 (1.9)                     | 13 (5.0)              |          |
| ≥T2c          | 83 (20.4)                   | 119 (35.2)            |          | 78 (30.2)                   | 80 (31.0)             |          |
| D’Amico risk class, n (%) | – –                      | <0.001                |          | – –                         | 0.073                 |          |
| Low           | 88 (21.7)                   | 15 (4.4)              |          | 23 (8.9)                    | 13 (5.0)              |          |
| Intermediate  | 142 (35.0)                 | 115 (34.0)            |          | 85 (32.9)                   | 105 (40.7)            |          |
| High          | 176 (43.3)                 | 208 (61.5)            |          | 150 (58.1)                  | 140 (54.3)            |          |
| Lymph node RT, n (%) | – –                      | 0.004                 |          | – –                         | 0.612                 |          |
| Yes           | 101 (24.9)                 | 116 (34.3)            |          | 85 (32.9)                   | 79 (30.6)             |          |
| No            | 305 (75.1)                 | 222 (65.7)            |          | 173 (67.1)                  | 177 (68.6)            |          |
| ADT, n (%)    | – –                        | 0.067                 |          | – –                         | 0.724                 |          |
| Yes           | 184 (45.3)                 | 176 (52.1)            |          | 138 (53.5)                  | 134 (51.9)            |          |
| No            | 222 (54.7)                 | 162 (47.9)            |          | 120 (46.5)                  | 124 (48.1)            |          |
| ADT duration (days) | 637 (352, 1022)    | 594 (274, 823)        | 0.129    | 609 (348, 1013)             | 548 (206, 777)        | 0.089    |
| MRI staging, n (%) | – –                      | 0.004                 |          | – –                         | 0.612                 |          |
| Yes           | 253 (62.3)                 | 79 (23.4)             | <0.001   | 154 (59.7)                  | 49 (19.0)             | <0.001   |
| No            | 153 (37.7)                 | 259 (76.6)            |          | 104 (40.3)                  | 209 (81.0)            |          |
| PET-CT after RT, n (%) | – –                      | 0.074                 |          | – –                         | 0.880                 |          |
| Yes           | 30 (7.4)                   | 38 (11.2)             |          | 23 (8.9)                    | 25 (9.7)              |          |
| No            | 376 (92.6)                 | 300 (88.8)            |          | 235 (91.1)                  | 333 (90.3)            |          |

Estimates were given as median (quartile 1, quartile 3) or frequency (percentage)

ADT androgen deprivation therapy, EBRT external beam radiation therapy, HDR-BT high-dose-rate brachytherapy, KPS Karnofsky performance status, PET-CT positron-emission tomography computed tomography, PSA prostate-specific antigen, RT radiation therapy

*p-values were calculated using Mann–Whitney U test for continuous and χ² test for categorical variables
of radiation therapy and the date of last news. Assessment of physician-recorded toxicity during radiation therapy was performed at baseline, at the end of treatment, 6 weeks after treatment, and at 6-month intervals thereafter. After 2 years, follow-up was changed to longer periods with annual examination. Gastrointestinal (GI) and genitourinary (GU) toxicity were scored using the Common Terminology Criteria for Adverse Events (CTCAE) v5.0. We assessed side effects systematically according to CTCAE v5.0 during follow-ups as well as by reviewing the patient files. Acute toxicity was defined as occurring between the start of radiation therapy and until 3 months after the end of radiation therapy. All subsequent follow-ups were included in the late toxicity evaluation.

Statistical analysis

A propensity score-matched analysis with a 1:1 ratio and a caliper of 0.1 was conducted to balance the significantly different baseline patient and histopathologic characteristics between the two treatment groups in order to minimize their effect on the oncologic outcome. A logistic regression model was used to calculate the propensity score, which included the following variables: patient age at the start of radiation therapy, Gleason score, initial PSA value, stage, use of ADT, and risk group according to D’Amico. All survival curves were estimated using the Kaplan–Meier method with the date of the end of radiation therapy as baseline time. For categorical data \( \chi^2 \) tests and for continuous variables Mann–Whitney U tests were used to compare baseline characteristics for unmatched and matched datasets. The log-rank test was used to compare survival curves. On the matched dataset, multivariable Cox proportional hazard models including hazard ratios (HR) with 95% confidence intervals (CI) were run using propensity score matching variables and type of radiation therapy treatment to uncover prognostic factors for oncologic outcome. For all statistical analyses, the R software environment for statistical computing and graphics (version 4.1; The R Foundation for Statistical Computing, Vienna, Austria) was used. All tests were two sided with statistical significance indicated by \( p < 0.05 \).

Results

Before propensity score matching, significant differences in patient age at the start of radiation therapy, initial PSA, Gleason score, stage, and D’Amico risk group were present. Patients in the combined treatment group had increased unfavorable disease characteristics (higher initial PSA, higher Gleason score, higher stage), and belonged more often to the high-risk group according to D’Amico. Irradiation of the pelvic lymph nodes occurred more often in the combined treatment group for the unmatched dataset. In the matched dataset, the pelvic lymph nodes were irradiated in 32.9% of all patients in the EBRT-only group and in 30.6% in the EBRT+ HDR-BT group (\( p = 0.612 \)). Additive ADT was given in 53.5% versus 51.9% (\( p = 0.724 \)) with a median duration (interquartile range) of 609 days (348–1013 days) versus 548 days (206–777 days) for the EBRT-only group versus the combined treatment group, respectively (\( p = 0.089 \)). All clinical, pathological, and treatment-related characteristics before and after propensity score matching are shown in Table 1.

To enable independent patient matching, propensity scores were calculated for the use of EBRT alone and EBRT plus HDR-BT boost, based on logistic regression analysis. Of the 744 patients treated either with EBRT or with combined EBRT and HDR-BT boost, 258 matched pairs with a sample size of 516 patients remained after
1:1 propensity score matching. The corresponding flow diagram is presented in Fig. 1.

For the matched cohort, median follow-up (interquartile range) was 95.3 months (59.2–132.4 months) in total. In the matched cohort (n = 516), the estimated 10-year bRFS was 82.0% (95% CI 76.0–88.4%) versus 76.4% (95% CI 70.8–82.3%) for EBRT versus EBRT + HDR-BT boost (p = 0.075), respectively (Fig. 2). The estimated 10-year MFS was 82.9% (95% CI 77.0–89.2%) versus 87.0% (95% CI 82.5–91.8%) with p = 0.195 and the estimated 10-year OS was 65.7% (95% CI 59.0–73.2%) versus 68.9% (95% CI 62.9–75.5%) with p = 0.303 (Figs. 3 and 4).

In the high-risk group (n = 290), bRFS was worse for EBRT + HDR-BT boost: the estimated 10-year bRFS was 76.3% (95% CI 67.1–86.8%) and 66.8% (95% CI 58.8–75.9%) for EBRT alone versus EBRT + HDR-BT boost, respectively (p = 0.039). No differences in bRFS between the two treatments for the intermediate-risk group were observable. MFS and OS were not significantly different between the two treatments for all risk groups. Positron-emission tomography computed tomography (PET-CT) imaging follow-up was distributed equally (Table 1).

The matched cohort was investigated by multivariable Cox proportional hazard model analysis for factors associated with oncological outcome. A higher Gleason score was prognostic for lower bRFS, MFS, and OS in multivariable analysis. Higher patient age at the start of radiation therapy was prognostic for decreased MFS. The treatment
Table 2  Multivariable Cox proportional hazard model analysis of the propensity score-matched cohort

| Variable            | BRFS \(N = 514\) | MFS \(N = 512\) | OS \(N = 514\) |
|---------------------|-----------------|-----------------|-----------------|
|                     | N   | HR  | 95% CI | p-value | HR  | 95% CI | p-value | HR  | 95% CI | p-value |
| Age at RT           | 516  | 0.98 | 0.95, 1.01 | 0.237 | 0.96 | 0.92, 0.99 | 0.007 | 1.02 | 0.99, 1.04 | 0.177 |
| PSA at diagnosis    | 516  | 1.00 | 1.00, 1.01 | 0.079 | 1.00 | 1.00, 1.01 | 0.662 | 1.00 | 0.99, 1.00 | 0.648 |
| Gleason score       |      |      |      |       |      |      |       |      |      |       |
| ≤ 6                 | 115  | Ref  | –     | –     | Ref  | –     | –     | Ref  | –     | –     |
| 7                   | 259  | 2.49 | 1.09, 5.68 | 0.031 | 3.20 | 0.94, 10.86 | 0.062 | 1.36 | 0.86, 2.15 | 0.189 |
| ≥ 8                 | 140  | 4.97 | 2.15, 11.47 | < 0.01 | 8.50 | 2.52, 28.63 | < 0.01 | 2.15 | 1.30, 3.56 | 0.003 |
| Stage               |      |      |      |       |      |      |       |      |      |       |
| ≤ T2a               | 339  | Ref  | –     | –     | Ref  | –     | –     | Ref  | –     | –     |
| T2b                 | 17   | 1.05 | 0.32, 3.44 | 0.936 | 1.97 | 0.58, 6.64 | 0.276 | 0.84 | 0.41, 1.75 | 0.647 |
| ≥ T2c               | 158  | 1.39 | 0.85, 2.27 | 0.192 | 1.75 | 0.95, 3.20 | 0.072 | 0.95 | 0.64, 1.41 | 0.801 |
| D’Amico risk class  |      |      |      |       |      |      |       |      |      |       |
| Intermediate        | 189  | Ref  | –     | –     | Ref  | –     | –     | Ref  | –     | –     |
| High                | 289  | 1.92 | 0.93, 3.94 | 0.077 | 1.42 | 0.55, 3.66 | 0.469 | 1.25 | 0.75, 2.07 | 0.391 |
| ADT                 |      |      |      |       |      |      |       |      |      |       |
| No                  | 242  | Ref  | –     | –     | Ref  | –     | –     | Ref  | –     | –     |
| Yes                 | 272  | 0.66 | 0.41, 1.07 | 0.088 | 0.88 | 0.48, 1.59 | 0.665 | 0.86 | 0.62, 1.20 | 0.376 |
| Treatment           |      |      |      |       |      |      |       |      |      |       |
| EBRT                | 257  | Ref  | –     | –     | Ref  | –     | –     | Ref  | –     | –     |
| EBRT + HDR-BT       | 257  | 1.48 | 0.94, 2.32 | 0.089 | 0.61 | 0.36, 1.04 | 0.068 | 0.89 | 0.64, 1.24 | 0.491 |

ADT androgen deprivation therapy, bRFS biochemical relapse-free survival, CI confidence interval, EBRT external beam radiation therapy, HDR-BT high-dose-rate brachytherapy, HR hazard ratio, MFS metastasis-free survival, NA not applicable, OS overall survival, PSA prostate-specific antigen, Ref reference, RT radiation therapy

group was not a prognostic factor for bRFS, MFS, and OS in multivariate analysis. The results of the Cox proportional hazard model analysis are summarized in Table 2.

Compared to combined EBRT + HDR-BT boost, EBRT showed significantly higher acute toxicities and higher cumulative 5-year late GI toxicity ≥ grade 2. Acute GU toxicity ≥ grade 2 occurred in 25.9% versus 11.8% \(p < 0.001\) and acute GI toxicity ≥ grade 2 in 11.8% versus 2.7% \(p < 0.001\), respectively. Cumulative 5-year late GU ≥ grade 2 toxicities were seen in 23.6% versus 19.2% \(p = 0.086\) and 5-year late GI ≥ grade 2 toxicities were observed in 11.1% versus 5.0% of the patients \(p = 0.002\), respectively. Cumulative 5-year late grade 3 GI toxicity occurred in 4.2% and 3.6% \(p = 0.401\) and GI toxicity in 1.0% and 0.3% \(p = 0.249\) in the EBRT alone versus combined treatment groups, respectively.

**Discussion**

Our study demonstrated excellent 10-year bRFS, MFS, and OS for both EBRT alone and combined EBRT + HDR-BT boost. The subgroup of high-risk prostate cancer patients showed increased bRFS for dose-escalated EBRT alone. This is in contrast to the literature: regarding the comparison of conventional fractionated EBRT and EBRT + HDR-BT boost, several studies reported an improvement in bRFS for the addition of HDR-BT boost to EBRT [7, 13–16]. In the 12-year update of a randomized controlled trial, Hoskin et al. reported a significant improvement in time to relapse in the HDR-BT boost arm compared to EBRT alone (median time to relapse 137 versus 82 months) [7]. There are several possible explanations for this discrepancy: Firstly, underdosing in the seminal vesicles cannot be excluded, since the seminal vesicles were not primarily within the HDR-BT boost target volume. Additionally, multiparametric MRI was not performed regularly for HDR-BT boost treatment planning, as this imaging method became an institutional standard only during the study period (Table 1). Therefore, disease extension into the seminal vesicles may have been undetected and undertreated in a subset of the patients [17]. Secondly, several comparative studies are retrospective and may suffer from underlying imbalances in patient and tumor characteristics, which makes a direct comparison of results challenging. Compensation of differences in baseline patient and tumor characteristics by propensity score matching is a strength of our study. Moreover, in several older trials, the EBRT-alone arm used prescription doses lower than 74 Gy (EQD2). This may have influenced the outcome and conclusions of those studies [7, 18, 19]. For example, the randomized trial by Hoskin et al. used a dose of 55 Gy in 20 fractions for the EBRT arm, which, for an \(\alpha/\beta\) value of 1.5 Gy, equals an EQD2 of 66.8 Gy. Our EBRT group received an EQD2 of about 83 Gy and
the HDR-BT boost group an EQD2 of 100 Gy (α/β 1.5 Gy), while the experimental arm in the Hoskin trial received an EQD2 of 92 Gy [7]. Despite higher EQD2, and in contrast to the Hoskin et al. trial, we did not observe a benefit of combined EBRT + HDR-BT boost over EBRT alone. The question arises of whether an HDR-BT boost is superior compared to dose-escalated EBRT above 80 Gy.

Regarding the validity of the linear quadratic (LQ) model for dose escalation above 80 Gy, the meta-analysis by Vogelius et al. highlighted an inconsistency of the existing data in light of the results of the HYPO-RT-PC trial. Widmark et al. reported an estimated α/β ratio of 3 Gy instead of 1.5 Gy as in the historical work of Brenner and Hall, which lead Vogelius et al. to suggest a non-constant α/β ratio and/or a saturation of biochemical control when 80 Gy EQD2 is exceeded [9, 20, 21]. The increased biochemical control reported by the FLAME trial shifted the likely hypotheses toward a decreasing relative biological effect with increasing fraction size when moving beyond moderate hypofractionation [22, 23]. Moreover, Vogelius et al. discussed the presence of a time factor of an estimated 0.31 Gy/d (95% CI 0.20–0.42) [25]. In our study, the overall treatment time (OTT) differed between the two groups, with about 6.5 weeks for EBRT only versus 9 weeks for EBRT + HDR-BT boost. As this difference could not be adjusted for by propensity score matching, an influence of OTT on outcome cannot be excluded. The applicability of the LQ model at high doses per fraction and the question of optimal dose and fractionation remains to be further investigated in randomized trials [9, 24].

Morton et al. and Greco et al. recently demonstrated the importance of fractionation. Morton et al. showed that single-fraction HDR-BT was inferior to two-fraction HDR-BT [26]. For dose-escalated prostate stereotactic body radiation therapy (SBRT) up to an EQD2 of 130 Gy, Greco et al. reported a 4-year bRFS of 75.0% versus 64.0% (HR 0.76; 90% CI 0.17–3.31) for SBRT with 5 × 9 Gy versus 1 × 24 Gy for unfavorable disease, respectively [27]. Two findings are of interest: firstly, one-fraction dose escalation appears to be inferior to dose escalation in more fractions. Secondly, the bRFS in the study of Greco et al. is lower than in a meta-analysis of over 6000 patients from Jackson et al., in which SBRT demonstrated a 5-year bRFS of 95.3% (95% CI 91.3–97.5%). Notably, increasing dose was significantly associated with improved bRFS, but only 38% of all studies included patients with high-risk disease and most studies did not report bRFS for high-risk disease separately [28].

Dose escalation above 80 Gy in unfavorable prostate cancer is supported by the results of the FLAME trial by Kerkmeijer et al.: dose escalation to 95 Gy for the dominant intraprostatic lesion improved 5-year bRFS up to 92% in a cohort with 84% high-risk patients [22]. For brachytherapy, the ASCENDE-RT trial impressively demonstrated improved bRFS with appliance of low-dose-rate brachytherapy boost over EBRT with 78 Gy, which supports brachytherapy as valid dose-escalation strategy [29]. To summarize, promising data for dose escalation in localized prostate cancer exists, but further randomized controlled trials are necessary to elucidate the interplay between biochemical control, the LQ model, and prescription of high doses per fraction for dose escalation above 80 Gy.

Besides benefits in bRFS, it is crucial to elucidate whether dose escalation influences clinically meaningful endpoints (for example, MFS and OS). Notably, MFS and OS were not significantly different for the two treatment modalities in the matched cohort of our study. In addition, dose escalation by EBRT is often limited by increased toxicity. In this context, dose escalation by HDR-BT has a favorable toxicity profile: in our study, late severe toxicities were not significantly different between the treatment cohorts. The combined treatment showed decreased acute toxicities grade ≥ 2 as well as lower moderate gastrointestinal toxicity compared to EBRT. Combined with excellent MFS and OS, EBRT + HDR-BT boost represents a competitive treatment regimen for intermediate- and high-risk prostate cancer.

Our study has limitations. Despite extensive propensity score matching, undetected differences in baseline characteristics between the treatment groups may have remained. Notably, we did not account for comorbidities and patients in the EBRT + HDR-BT group were, despite matching, younger, which could have influenced the outcome, especially overall survival. Differences in MRI staging may have led to a skewed stage distribution (Table 1): in the matched cohort, 154 out of 258 cases (59.7%) received MRI before treatment in the EBRT-only group, whereas only 49 out of 258 cases (19.0%) had MRI in the EBRT + HDR-BT group (p = < 0.001). Moreover, patients with known seminal vesicle involvement may have been preferably treated with EBRT alone, possibly resulting in a negative selection of the EBRT group.

**Conclusion**

Dose-escalated EBRT with an EQD2 above 80 Gy and combined EBRT + HDR-BT boost showed no significant differences in outcome in a large propensity score-matched cohort. EBRT + HDR-BT boost demonstrated a trend to worse biochemical relapse-free survival compared to EBRT alone for the subgroup of high-risk prostate cancers. The combined treatment provided a favorable toxicity profile with lower acute toxicity and late gastrointestinal toxicity ≥ grade 2. EBRT as well as EBRT + HDR-BT boost
are both excellent options for dose-escalating radiotherapy above 80 Gy (EQD2) in localized prostate cancer.

Acknowledgements We would like to thank Dr. Ulrich Stefanelli for statistical advice.

Funding No funds, grants, or other support was received.

Author Contribution J. Tamihardja, B. Polat, and M. Flentje contributed to study conception and design. The data were acquired by J. Tamihardja, I. Lawrenz, P. Lutyj, and S. Weick. Data analysis and interpretation were performed by J. Tamihardja. Manuscript editing and preparation was performed by J. Tamihardja, M. Guckenberger, B. Polat, and M. Flentje contributed to the manuscript review.

Funding Open Access funding enabled and organized by Projekt DEAL.

Declarations

Conflict of interest J. Tamihardja, I. Lawrenz, P. Lutyj, S. Weick, M. Guckenberger, B. Polat, and M. Flentje declare that they have no competing interests.

Ethical standards All procedures performed in studies involving human participants or on human tissue were in accordance with the ethical standards of the institutional and/or national research committee and with the 1975 Helsinki declaration and its later amendments or comparable ethical standards. Consent to participate: Informed consent was obtained from all individual participants included in the study.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Chao KK et al (2006) Clinicopathologic analysis of extracapsular extension in prostate cancer: should the clinical target volume be expanded posterolaterally to account for microscopic extension? Int J Radiat Oncol Biol Phys 65(4):999–1007. https://doi.org/10.1016/j.ijrobp.2006.02.039
2. Al-Mamgani A et al (2011) Dose escalation and quality of life in patients with localized prostate cancer treated with radiotherapy: long-term results of the Dutch randomized dose-escalation trial (CKTO 96-10 trial). Int J Radiat Oncol Biol Phys 79(4):1004–1012. https://doi.org/10.1016/j.ijrobp.2009.12.039
3. Deanmey PE et al (2005) Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. Br J Cancer 92(3):488–498. https://doi.org/10.1038/sj.bjc.6602301
4. Deanmey PE et al (2007) Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol 8(6):475–487. https://doi.org/10.1016/S1470-2045(07)70143-2
5. Kuban DA et al (2008) Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 70(1):67–74. https://doi.org/10.1016/j.ijrobp.2007.06.054
6. Zietman AL et al (2010) Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09. J Clin Oncol 28(7):1106–1111. https://doi.org/10.1200/JCO.2009.25.8475
7. Hoskin PJ et al (2021) Randomised trial of external-beam radiotherapy alone or with high-dose-rate brachytherapy for prostate cancer: mature 12-year results. Radiother Oncol 154:214–219. https://doi.org/10.1016/j.radonc.2020.09.047
8. Vogelius IR, Bentzen SM (2018) Dose response and fractionation sensitivity of prostate cancer after external beam radiation therapy: a meta-analysis of randomized trials. Int J Radiat Oncol Biol Phys 100(4):858–865. https://doi.org/10.1016/j.ijrobp.2017.12.011
9. Vogelius IR, Bentzen SM (2020) Diminishing returns from ultrahypofractionated radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 107(2):299–304. https://doi.org/10.1016/j.ijrobp.2020.01.010
10. D’Amico AV et al (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280(11):969–974. https://doi.org/10.1001/jama.280.11.969
11. Tamihardja J et al (2021) Moderately hypofractionated radiotherapy for localized prostate cancer: updated long-term outcome and toxicity analysis. Strahlenther Onkol 197(2):124–132. https://doi.org/10.1007/s00066-020-01678-w
12. Tamihardja J et al (2021) Two-weekly high dose-rate brachytherapy boost after external beam radiotherapy for localized prostate cancer: long-term outcome and toxicity analysis. Front Oncol 11:764536. https://doi.org/10.3389/fonc.2021.764536
13. Kishan AU et al (2018) Radical prostatectomy, external beam radiotherapy, or external beam radiotherapy with brachytherapy boost and disease progression and mortality in patients with Gleason score 9–10 prostate cancer. JAMA 319(9):896–905. https://doi.org/10.1001/jama.2018.0587
14. Khor R et al (2013) Direct 2-arm comparison shows benefit of high-dose-rate brachytherapy boost vs external beam radiation therapy alone for prostate cancer. Int J Radiat Oncol Biol Phys 85(3):679–685. https://doi.org/10.1016/j.ijrobp.2012.07.006
15. Zwahlen DR et al (2010) High-dose-rate brachytherapy in combination with conformal external beam radiotherapy in the treatment of prostate cancer. Brachytherapy 9(1):27–35. https://doi.org/10.1016/j.bray.2009.04.007
16. Kestin LL et al (2000) Matched-pair analysis of conformal high-dose-rate brachytherapy boost versus external-beam radiation therapy alone for locally advanced prostate cancer. J Clin Oncol 18(15):2869–2880. https://doi.org/10.1200/JCO.2000.18.15.2869
17. Hegde JV et al (2017) Pretreatment 3T multiparametric MRI staging predicts for biochemical failure in high-risk prostate cancer treated with combination high-dose-rate brachytherapy and external beam radiotherapy. Brachytherapy 16(6):1106–1112. https://doi.org/10.1016/j.bray.2017.07.008
18. Wedde TB et al (2019) Ten-year survival after high-dose-rate brachytherapy combined with external beam radiation therapy in high-risk prostate cancer: a comparison with the Norwegian SPCG-7 cohort. Radiother Oncol 132:211–217. https://doi.org/10.1016/j.radonc.2018.10.013
19. Oshikane T et al (2021) A comparative study of high-dose-rate brachytherapy boost combined with external beam radiation ther-
apy versus external beam radiation therapy alone for high-risk prostate cancer. J Radiat Res 62(3):525–532. https://doi.org/10.1093/jrr/rrab006

20. Widmark A et al (2019) Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. Lancet 394(10196):385–395. https://doi.org/10.1016/S0140-6736(19)31131-6

21. Brenner DJ, Hall EJ (1999) Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 43(5):1095–1101. https://doi.org/10.1016/S0360-3016(98)00438-6

22. Kerkmeijer LGW et al (2021) Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: results from the FLAME randomized phase III trial. J Clin Oncol 39(7):787–796. https://doi.org/10.1200/JCO.20.02873

23. Vogelius IR, Bentzen SM (2021) Radiation dose escalation for early prostate cancer: reigniting the FLAME? J Clin Oncol 39(27):3085–3086. https://doi.org/10.1200/JCO.21.00586

24. Roberts SA et al (2014) A modelled comparison of prostate cancer control rates after high-dose-rate brachytherapy (3145 multicentre patients) combined with, or in contrast to, external-beam radiotherapy. Radiother Oncol 111(1):114–119. https://doi.org/10.1016/j.radonc.2014.01.008

25. Vogelius IR, Bentzen SM (2013) Meta-analysis of the alpha/beta ratio for prostate cancer in the presence of an overall time factor: bad news, good news, or no news? Int J Radiat Oncol Biol Phys 85(1):89–94. https://doi.org/10.1016/j.ijrobp.2012.03.004

26. Morton G et al (2020) Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: efficacy results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy. Radiother Oncol 146:90–96. https://doi.org/10.1016/j.radonc.2020.02.009

27. Greco C et al (2021) Safety and efficacy of virtual prostatectomy with single-dose radiotherapy in patients with intermediate-risk prostate cancer: results from the PROSINT phase 2 randomized clinical trial. JAMA Oncol 7(5):700–708. https://doi.org/10.1001/jamaoncol.2021.0039

28. Jackson WC et al (2019) Stereotactic body radiation therapy for localized prostate cancer: a systematic review and meta-analysis of over 6,000 patients treated on prospective studies. Int J Radiat Oncol Biol Phys 104(4):778–789. https://doi.org/10.1016/j.ijrobp.2019.03.051

29. Morris WJ et al (2017) Androgen suppression combined with elective nodal and dose escalated radiation therapy (the ASCENDE-RT trial): an analysis of survival endpoints for a randomized trial comparing a low-dose-rate brachytherapy boost to a dose-escalated external beam boost for high- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys 98(2):275–285. https://doi.org/10.1016/j.ijrobp.2016.11.026